SpaceX IPO vs. Rocket Lab: Which Space Economy Stock Is the Better Buy?

The article argues that SpaceX's $1.77 trillion valuation leaves limited upside, while Rocket Lab may offer better risk-reward given 2025 revenue of about $602 million, a backlog above $2 billion, and Q1 2026 revenue of $200 million. Rocket Lab also completed 21 launches in 2025 with a 100% mission success rate and won an $816 million Space Development Agency contract, though it remains unprofitable and Neutron has been delayed. Overall, this is an opinion-driven comparison rather than a direct market-moving catalyst.

Analysis

The market is implicitly splitting the space stack into two different trades: a quality monopoly at any price versus an option on second-tier platform consolidation. That matters because the capital markets are unlikely to fund every space name equally if risk appetite tightens; when private-market multiples compress, later-stage satellite and launch companies with real revenue but no profitability get repriced first, while infrastructure winners with defense-backed backlog become relative havens. The second-order effect is that suppliers of propulsion, avionics, and specialty manufacturing may see order visibility improve even if headline launch multiples wobble.

Rocket Lab’s real edge is not launch—it is vertical integration across spacecraft subsystems, which creates a broader procurement footprint and raises switching costs with government customers. The Neutron program is the binary: success would move the company from niche launcher to credible mid-lift competitor, but any further delay pushes the equity into a “good business, bad stock” regime where backlog growth is not enough to offset dilution and capex. In contrast, the dominant incumbent’s valuation leaves very little room for execution slippage, so its upside is increasingly driven by multiple expansion rather than fundamental surprise.

The contrarian read is that the current debate may be underweighting defense procurement as a cushion. A meaningful portion of space spend is becoming quasi-infra spending tied to national security, which tends to be stickier than commercial launch cycles and can support multi-year revenue ramps for the ecosystem even in a risk-off tape. That argues for owning the picks-and-shovels exposure rather than betting purely on headline launch share.

Near term, the setup is less about days than 6-18 months: any Neutron milestone, backlog conversion, or margin inflection could re-rate the smaller name quickly, while continued slippage would likely trigger de-risking. The main reversal catalyst is operational execution failure on the new rocket, because that would force investors to value the company on current launch economics alone, where scale is still insufficient to justify premium multiples.

Key Decisions for Investors

• Long RKLB / short a basket of high-multiple private-space proxies if available; otherwise use a small-size long RKLB with a hard stop on any additional Neutron delay announcement. Target horizon: 6-12 months; thesis only works if execution reduces perceived binary risk.
• Buy RKLB Jan-2027 call spreads to express asymmetric upside on Neutron without paying full equity volatility. Best risk/reward if bought on weakness after any launch-timeline setback.
• Pair trade: long defense-linked space suppliers and infrastructure names, short unprofitable launch-only exposure. This captures the second-order benefit of procurement spend shifting toward resilient government programs.
• Avoid chasing the dominant incumbent at current valuation multiples; if you need exposure, prefer a staged entry after any miss or guidance reset, because the stock now trades as a flawless-execution asset.
• If RKLB confirms Neutron progress on schedule, add on the first post-news consolidation rather than the initial spike; the re-rating should persist for weeks, but the best entry is usually after momentum cools.